Side-by-side · Research reference

EpitalonvsHumanin

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AHuman-MechanisticAUTO-DRAFTED8/37 cited

BAnimal-StrongHUMAN-REVIEWED14/52 cited

Epitalon

Pineal bioregulator · Telomerase activator

5–10 mgPer cycle doseKhavinson 2003

HumanMechanisticKhavinson 2003

HoursHalf-life (est)

SQ or IM · Abdomen · Daily for 10–20 days

Humanin

Mitochondrial-Derived Peptide · Cytoprotective

24-AAPeptide lengthZhu 2022

mtDNAEncoded originZhu 2022 Shahzaib 2026

Bax/BimPrimary targetZhu 2022 Morris 2021

SQ · Experimental

01Mechanism of Action

Parameter

Epitalon

Humanin

Primary target

Telomerase activity (proposed); pineal melatonin axis modulationKhavinson 2003

Intracellular: Bax, Bim, tBid (pro-apoptotic Bcl-2 family). Extracellular: FPRL1/2 G-protein-coupled receptorsZhu 2022 Lue 2021

Pathway

Activation of telomerase reverse transcriptase (hTERT) in somatic cells; pineal-axis modulation supports endogenous melatoninKhavinson 2003

Humanin binds Bax/Bim → inhibits mitochondrial outer membrane permeabilization (MOMP) → blocks cytochrome c release → prevents caspase activation → cell survival

Downstream effect

Telomere elongation, improved sleep architecture, reported lifespan extension in aged miceKhavinson 2003

Suppression of apoptosis, mitochondrial stabilization, reduced oxidative stress, preservation of germ cells and neurons under stressZhu 2022 Lue 2021 Velentza 2024

Feedback intact?

—

Not applicable — peptide acts as anti-apoptotic signal, not hormonal axis

Origin

Synthetic 4-AA peptide derived from epithalamin (a natural pineal extract)Khavinson 2003

Encoded by short open reading frame in mitochondrial 16S rRNA gene (MTRNR2). 24-28 amino acids. 13 homologous variants (MTRNR2L1-L13) identified.Zhu 2022 Shahzaib 2026

Antibody development

—

Not reported in animal models

02Dosage Protocols

Parameter

Epitalon

Humanin

Standard dose

5–10 mg / day for 10–20 days, 1–2× per yearKhavinson 2003

Anecdotal community protocol. Russian clinical literature uses similar cycling.

—

Frequency

Once daily during a cycle

Daily (IP)

Lower / starter dose

2.5 mg / day

—

Evidence basis

In-vitro telomerase + Russian clinical trialsKhavinson 2003

Animal models (rat, mouse)Huang 2025 El 2022 Velentza 2024

Duration

10–20 day cycles, 1–2× per year

8–12 weeks in animal studies

Reconstitution

Bacteriostatic water

—

Timing

Pre-sleep preferred (pineal alignment)

—

Half-life

Hours (estimated)

—

Standard experimental dose (HNG)

—

4 mg/kg IP (rat)

Most common dose in rodent models.

Ex vivo bone culture

—

1 µg/mL

Protective against venetoclax-induced bone growth retardation.

Human data

—

None — no clinical trials reported

Analog (HNG)

—

Gly[14]-humanin — more potent variant

Substitution at position 14 enhances cytoprotective activity.

03Metabolic / Fat Loss Evidence

Parameter

Epitalon

Humanin

Direct fat loss evidence

—

None

Mechanism overlap

—

Mitochondrial health may indirectly influence metabolic efficiency, but no quantified effect

04Side Effects & Safety

Parameter

Epitalon

Humanin

Injection site reaction

Mild irritation

Not reported in animal studies (IP route)

Sleep architecture

Improved subjective sleep quality (anecdotal)

—

Cancer risk

Theoretical via telomerase activation in pre-malignant cells

—

Long-term safety

Limited Western RCT data

—

Pregnancy / OB

Avoid

—

Antibody formation

Not reported

—

Animal model safety

—

Well-tolerated in rat and mouse studies at 4 mg/kg for 8–12 weeks

Human safety data

—

None — no clinical trials

Theoretical fibrillation risk

—

Induces amyloid-like fibrillation of Bax/BID. Long-term sequelae unknown.

Reproductive safety

—

Protective in POI model (cyclophosphamide-induced), no adverse effects on fertility notedHuang 2025

Absolute Contraindications

Epitalon

·Pregnancy / breastfeeding
·Active malignancy or pre-malignant state

Humanin

·Unknown — no human data

Relative Contraindications

Epitalon

·Family history of cancer

Humanin

·Active malignancy (theoretical risk of anti-apoptotic effect on tumour cells)

05Administration Protocol

Parameter

Epitalon

Humanin

1. Reconstitution

Add 1–2 mL bacteriostatic water to 10 mg vial → 5–10 mg/mL.

Intraperitoneal (IP) in animal models. Subcutaneous route untested. No human protocols exist.

2. Injection site

SQ — abdomen preferred. Rotate sites.

Synthetic peptide reconstituted in sterile saline or PBS. No commercial formulation available.

3. Timing

Pre-sleep preferred to align with pineal axis.

Daily administration in animal studies. Optimal timing not characterized.

4. Storage

Lyophilised: room temp, light-protected. Reconstituted: refrigerate ≤30 days.

Lyophilised powder: -20 °C. Reconstituted: 4 °C, use within 7 days. Avoid freeze-thaw cycles.

5. Needle

29–31G, 4–8 mm insulin syringe.

No FDA approval, no IND, no clinical trials. Experimental research tool only.

06Stack Synergy

Epitalon

— no documented stacks

Humanin

+ MOTS-c

Multi-pathway

View MOTS-c →

Both are mitochondrial-derived peptides. MOTS-c enhances metabolic efficiency and insulin sensitivity via AMPK activation, while humanin prevents mitochondrial apoptosis. Combined, they address mitochondrial function (MOTS-c) and survival signaling (humanin), supporting cellular resilience under metabolic and oxidative stress.

Humanin: 4 mg/kg IP · daily (animal model)
MOTS-c: 5 mg/kg IP · daily (animal model)
Frequency: Once daily
Primary benefit: Mitochondrial health, metabolic efficiency, anti-apoptotic signaling